Amgen Financials
AMGN Stock | USD 294.00 0.53 0.18% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Net Profit Margin | 0.18 | 0.2383 |
|
| |||||
Return On Assets | 0.12 | 0.0691 |
|
| |||||
Return On Equity | 1.13 | 1.0778 |
|
| |||||
Debt Equity Ratio | 10.89 | 10.3679 |
|
| |||||
Current Ratio | 1.57 | 1.6492 |
|
|
Investors should never underestimate Amgen's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Amgen's cash flow, debt, and profitability to make informed and accurate decisions about investing in Amgen Inc.
Net Income |
|
Amgen | Select Account or Indicator |
Understanding current and past Amgen Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Amgen's financial statements are interrelated, with each one affecting the others. For example, an increase in Amgen's assets may result in an increase in income on the income statement.
Amgen Earnings Geography
Amgen Stock Summary
Amgen competes with Eliem Therapeutics, HCW Biologics, Scpharmaceuticals, Milestone Pharmaceuticals, and Seres Therapeutics. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. It employs 24200 people.Foreign Associate | Mexico |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US0311621009 |
CUSIP | 031162100 |
Location | California; U.S.A |
Business Address | One Amgen Center |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.amgen.com |
Phone | 805 447 1000 |
Currency | USD - US Dollar |
Amgen Key Financial Ratios
Return On Equity | 0.56 | ||||
Profit Margin | 0.13 % | ||||
Operating Margin | 0.24 % | ||||
Price To Sales | 4.87 X | ||||
Revenue | 28.19 B |
Amgen Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 102.0B | |
Other Current Liab | 8.5B | 9.2B | 9.9B | 11.2B | 13.6B | 14.3B | |
Net Debt | 23.9B | 26.7B | 25.3B | 31.3B | 53.7B | 56.4B | |
Retained Earnings | (21.3B) | (21.4B) | (24.6B) | (28.6B) | (26.5B) | (25.2B) | |
Cash | 6.0B | 6.3B | 8.0B | 7.6B | 10.9B | 11.5B | |
Net Receivables | 4.1B | 4.5B | 4.9B | 5.6B | 7.9B | 8.3B | |
Other Current Assets | 1.9B | 2.1B | 2.4B | 2.4B | 1.9B | 2.7B | |
Total Liab | 50.0B | 53.5B | 54.5B | 61.5B | 90.9B | 95.5B | |
Total Current Assets | 18.4B | 21.1B | 19.4B | 22.2B | 30.3B | 15.2B | |
Short Term Debt | 3.0B | 244M | 232M | 1.7B | 1.6B | 1.0B | |
Inventory | 3.6B | 3.9B | 4.1B | 4.9B | 9.5B | 10.0B | |
Accounts Payable | 1.4B | 1.4B | 1.4B | 1.6B | 1.6B | 1.7B | |
Capital Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Common Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Other Assets | 955M | 1.3B | 6.5B | 2.2B | 2.5B | 1.4B | |
Long Term Debt | 27.0B | 32.9B | 33.2B | 37.4B | 63.2B | 66.3B | |
Good Will | 14.7B | 14.7B | 14.9B | 15.5B | 18.6B | 14.4B | |
Intangible Assets | 19.4B | 16.6B | 15.2B | 16.1B | 32.6B | 34.3B | |
Other Liab | 9.9B | 9.0B | 9.1B | 7.9B | 9.1B | 5.1B | |
Net Tangible Assets | (24.4B) | (21.9B) | (23.4B) | (27.9B) | (25.2B) | (23.9B) | |
Long Term Debt Total | 27.0B | 32.9B | 33.2B | 37.4B | 43.0B | 29.9B |
Amgen Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 1.3B | 1.3B | 1.2B | 1.4B | 2.9B | 3.0B | |
Total Revenue | 23.4B | 25.4B | 26.0B | 26.3B | 28.2B | 29.6B | |
Gross Profit | 19.0B | 19.3B | 19.5B | 19.9B | 19.7B | 20.7B | |
Operating Income | 9.7B | 5.8B | 6.0B | 5.3B | 7.9B | 4.1B | |
Ebit | 9.7B | 9.3B | 9.1B | 8.8B | 7.9B | 4.6B | |
Ebitda | 10.4B | 12.9B | 12.5B | 12.1B | 7.9B | 5.4B | |
Cost Of Revenue | 4.4B | 6.2B | 6.5B | 6.4B | 8.5B | 8.9B | |
Income Before Tax | 9.1B | 8.1B | 6.7B | 7.3B | 7.9B | 4.0B | |
Net Income | 7.8B | 7.3B | 5.9B | 6.6B | 6.7B | 7.1B | |
Income Tax Expense | 1.3B | 869M | 808M | 794M | 1.1B | 830.4M | |
Research Development | 4.1B | 4.2B | 4.8B | 4.4B | 4.8B | 2.9B | |
Tax Provision | 1.3B | 869M | 808M | 794M | 1.2B | 1.4B | |
Interest Income | 928M | 674M | 753M | 256M | 230.4M | 218.9M | |
Net Interest Income | (536M) | (1.0B) | (1.2B) | (1.4B) | (2.5B) | (2.3B) |
Amgen Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (66M) | (215M) | (165M) | (742M) | 491M | 515.6M | |
Change In Cash | (908M) | 229M | 1.7B | (360M) | 3.3B | 3.5B | |
Free Cash Flow | 8.5B | 9.9B | 8.4B | 8.8B | 7.4B | 4.5B | |
Depreciation | 2.2B | 3.6B | 3.4B | 3.4B | 4.1B | 4.3B | |
Other Non Cash Items | (186M) | (195M) | 1.3B | 1.3B | (991M) | (941.5M) | |
Capital Expenditures | 618M | 608M | 880M | 936M | 1.1B | 663.6M | |
Net Income | 7.8B | 7.3B | 5.9B | 6.6B | 6.7B | 3.4B | |
End Period Cash Flow | 6.0B | 6.3B | 8.0B | 7.6B | 10.9B | 11.5B | |
Change To Netincome | 205M | (152M) | 3.4B | 485M | 557.8M | 379.4M | |
Investments | 20.0B | (4.7B) | 733M | (6.0B) | (2.6B) | (2.5B) | |
Change Receivables | (504M) | (427M) | (429M) | (746M) | (671.4M) | (637.8M) | |
Net Borrowings | (4.5B) | 2.5B | 795M | 6.6B | 6.0B | 6.3B | |
Dividends Paid | 3.5B | 3.8B | 4.0B | 4.2B | 4.6B | 2.9B |
Amgen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Amgen's current stock value. Our valuation model uses many indicators to compare Amgen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Amgen competition to find correlations between indicators driving Amgen's intrinsic value. More Info.Amgen Inc is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.08 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Amgen Inc is roughly 12.11 . At this time, Amgen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Amgen's earnings, one of the primary drivers of an investment's value.Amgen's Earnings Breakdown by Geography
Amgen Inc Systematic Risk
Amgen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Amgen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Amgen Inc correlated with the market. If Beta is less than 0 Amgen generally moves in the opposite direction as compared to the market. If Amgen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Amgen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Amgen is generally in the same direction as the market. If Beta > 1 Amgen moves generally in the same direction as, but more than the movement of the benchmark.
Amgen Thematic Clasifications
Amgen Inc is part of several thematic ideas from Health Management to Drugs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasHealth Management | View | ||
Drugs | View | ||
Baby Boomer Prospects | View | ||
Robots And Drones | View | ||
Giant Impact | View | ||
Cash Cows | View | ||
Macroaxis Index | View |
Today, most investors in Amgen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Amgen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Amgen growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Amgen November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Amgen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Amgen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Amgen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Amgen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Amgen's daily price indicators and compare them against related drivers.
Information Ratio | (0.16) | |||
Maximum Drawdown | 9.43 | |||
Value At Risk | (1.90) | |||
Potential Upside | 1.67 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.621 | Dividend Share 8.88 | Earnings Share 7.83 | Revenue Per Share 60.641 | Quarterly Revenue Growth 0.232 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.